Previous 10 |
home / stock / mnkpf / mnkpf news
Mallinckrodt Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System PR Newswire — If 510(k) cleared, this next-generation investigational inhaled nitric oxide delivery system would be the latest in a long line of dual channel del...
Mallinckrodt Announces Appointment of Lisa French as Chief Commercial Officer PR Newswire DUBLIN , Sept. 19, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, tod...
Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS) PR Newswire – Terlivaz is the first and only FDA-approved treatment for adults with HRS involving rapid reduction in kidney func...
Mallinckrodt plc Provides Update on Executive Committee PR Newswire DUBLIN , Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today provided an upda...
Mallinckrodt Announces Appointment of Karen Ling to Its Board of Directors PR Newswire DUBLIN , Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, tod...
Mallinckrodt press release ( NYSE: MNK ): Q2 net loss of $257.2M Revenue of $468.7M (-14.2% Y/Y). Bryan Reasons, EVP and Chief Financial Officer, said, "Having eliminated more than $1.3 billion in debt principal and closed a new $200 million accounts receivable financi...
Mallinckrodt plc Reports Second Quarter 2022 Financial Results and Provides 2022 Financial Guidance PR Newswire Focused on Advancing Branded Pipeline with Anticipated Launches and Bringing Existing Products to New Markets and Geographies Committed to Strengthen...
MALLINCKRODT TO REPORT EARNINGS RESULTS FOR SECOND QUARTER 2022 AND PROVIDE BUSINESS UPDATE PR Newswire DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it wil...
News, Short Squeeze, Breakout and More Instantly...
Mallinckrodt Company Name:
MNKPF Stock Symbol:
OTCMKTS Market:
Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance PR Newswire Made Solid Progress on Launch of Terlivaz® with Significant Medical Community Interest Appointed Chief Scientific Officer with Proven Record of Executi...
Mallinckrodt to Present at Cowen's 43rd Annual Health Care Conference PR Newswire DUBLIN , Feb. 16, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson , President ...
Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance PR Newswire Launched Terlivaz ® Following U.S. Food and Drug Administration (FDA) Approval in September; Submitted U.S. FDA Premarket Notification Application for Next-Generat...